Shares of Owens & Minor (NYSE:OMI) have earned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $23.06.
A number of research analysts have recently commented on OMI shares. JPMorgan Chase reiterated an “underweight” rating and set a $22.00 target price on shares of Owens & Minor in a research report on Tuesday, December 19th. Zacks Investment Research downgraded Owens & Minor from a “hold” rating to a “strong sell” rating in a research report on Friday, December 22nd. ValuEngine downgraded Owens & Minor from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Bank of America started coverage on Owens & Minor in a research report on Tuesday, February 27th. They set a “buy” rating and a $19.00 target price for the company. Finally, Barclays started coverage on Owens & Minor in a research report on Thursday, March 8th. They set an “underweight” rating and a $16.00 target price for the company.
OMI traded down $0.14 during trading on Wednesday, reaching $15.62. 164,288 shares of the company traded hands, compared to its average volume of 1,442,016. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.67 and a quick ratio of 0.91. Owens & Minor has a 12-month low of $14.26 and a 12-month high of $34.97. The firm has a market cap of $969.49, a P/E ratio of 9.71, a price-to-earnings-growth ratio of 0.97 and a beta of 1.06.
The business also recently declared a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Thursday, March 15th were given a $0.26 dividend. The ex-dividend date of this dividend was Wednesday, March 14th. This is an increase from Owens & Minor’s previous quarterly dividend of $0.26. This represents a $1.04 dividend on an annualized basis and a yield of 6.66%. Owens & Minor’s dividend payout ratio (DPR) is currently 64.60%.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC bought a new stake in Owens & Minor in the fourth quarter worth $1,269,000. Vident Investment Advisory LLC lifted its position in Owens & Minor by 19.5% in the fourth quarter. Vident Investment Advisory LLC now owns 103,564 shares of the company’s stock worth $1,956,000 after buying an additional 16,912 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in Owens & Minor by 341.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,626 shares of the company’s stock worth $200,000 after buying an additional 8,219 shares during the last quarter. Teachers Advisors LLC lifted its position in Owens & Minor by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 113,226 shares of the company’s stock worth $2,138,000 after buying an additional 4,360 shares during the last quarter. Finally, Paloma Partners Management Co lifted its position in Owens & Minor by 540.4% in the fourth quarter. Paloma Partners Management Co now owns 83,932 shares of the company’s stock worth $1,585,000 after buying an additional 70,825 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.
Owens & Minor Company Profile
Owens & Minor, Inc is a healthcare services company that connects the world of medical products to the point of care. The Company provides supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies and devices. The Company’s segments include Domestic, International and Clinical & Procedural Solutions (CPS).
Receive News & Ratings for Owens & Minor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Owens & Minor and related companies with MarketBeat.com's FREE daily email newsletter.